Success Stories: Research Associate from Bangladesh in the Field of Pharmaceutical Sciences with Approved NIW Petition Now Has a Green Card

Client’s Testimonial:

“Good morning. Thank you for email. I am very happy to inform you that I have been received the I-140 approval notice from USCIS also. Thanks for your all co-operation. I really appreciate the way you work and your best professionalism. […] Again I am very lucky to have you with me. I really happy and wish to congratulate you to handle my case confidently.”

On May 3^rd, 2016, we received another EB-2 NIW (National Interest Waiver) approval for a Research Associate in the Field of Pharmaceutical Sciences (Approval Notice).

General Field: Pharmaceutical Sciences

Position at the Time of Case Filing: Research Associate

Country of Origin: Bangladesh

Service Center: Texas Service Center (TSC)

State of Residence at the Time of Filing: New York

Approval Notice Date: May 3^rd, 2016

Processing Time: 9 months, 3 days

Case Summary:

A recent client of ours was described as “…a biomedical researcher of considerable ability. Her findings have profound significance to the international community of oncological researchers and to the nation’s healthcare and pharmaceutical industries. This wide influence marks [Client] as being an especially outstanding scientist.”

The quote above is excerpted from a recommendation letter contributed by a well-known clinical scientist. He was not alone in this strong show of support for our client and was joined by three other expert pharmaceutical scientists, all of whom signed recommendation letters. These letters were incorporated into our client’s EB-2 NIW (National Interest Waiver) petition dossier which North America Immigration Law Group (WeGreened.com) submitted to the USCIS on her behalf.

What else did the petition contain?

Besides recommendation letters, our client’s comprehensive EB-2 NIW petition packet was composed of details on her pharmaceutical science research. We noted her identification of novel biomarkers for the development of enhanced targeted drug delivery systems as well as other innovative findings. We demonstrated to the USCIS that our client’s work impacts the American healthcare industry and overall public well-being. Further research efforts are contributing to the country’s oncological research community by directly targeting tumor endothelial cells to halt the pathogenesis of the deadly disease. With a Ph.D. in Pharmacy and a myriad of professional achievements under her belt, our client is undoubtedly a leading light in the field. Her work has resulted in the publication of 14 journal articles, one book chapter, and numerous conference papers, all of which had amassed 206 citations when we filed the case.

Filing I-485 applications while the I-140 is pending approval:

The USCIS spent 9 months and 3 days adjudicating our client’s EB-2 NIW petition before granting their approval. A little over a month later, our client received news that her and her family’s I-485 applications had been approved. As the final step in the green card process, an approved I-485 means that our client and her dependents are now official U.S. permanent residents. The reason why they only waited a month between approval notices is because our client chose to file her I-485 application while her I-140 EB-2 NIW was pending approval. Although many green card applicants tend to wait for the I-140 to be approved before filing an I-485 application, our client saved between 4-9 months doing what she did. We congratulate her and her family for obtaining their green cards, and we wish them the very best as they embark on their exciting new journey as American permanent residents.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.